Skip to Main Content
Table 4.

Prevalence and attribution of HPV types in vulvar cancers

YearFirst authornMultitype infections (%)Percentage of specimens testing positive for individual HPV types
Any HPV type*
6111618313335394551525658596668707382
Vulvar squamous cell cancers (4, 5, 48, 52)                        
2001 Carter 110 8.1 8.1 0.0 59.1 5.8 2.3 9.3 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 75.6 
1999 Pinto 16 0.0 0.0 0.0 37.5 0.0 0.0 6.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0  50.0 
1996 Kim 18 0.0 5.6 0.0 27.8 5.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0    38.9 
1995 Monk 53  1.9  50.9 5.7                60.0 
                        
Pooled prevalence  197 5.8 5.2 0.0 52.3 5.2 1.7 7.5 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 65.3 
95% CI, lower    2.8 0.0 45.3 2.8 0.5 4.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0  
95% CI, upper    9.6 3.1 59.1 9.6 5.9 13.6 2.6 3.1 3.1 3.1 4.6 3.1 3.1 3.1 3.1 3.1 3.6 3.6 4.3  
                        
Multitype adjusted  120  3.6 0.0 49.5 4.2 1.7 6.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0  
95% CI, lower    1.4 0.0 40.7 1.8 0.5 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0  
95% CI, upper    8.6 3.1 58.3 9.5 5.9 11.8 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.6 3.6 4.3  
YearFirst authornMultitype infections (%)Percentage of specimens testing positive for individual HPV types
Any HPV type*
6111618313335394551525658596668707382
Vulvar squamous cell cancers (4, 5, 48, 52)                        
2001 Carter 110 8.1 8.1 0.0 59.1 5.8 2.3 9.3 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 75.6 
1999 Pinto 16 0.0 0.0 0.0 37.5 0.0 0.0 6.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0  50.0 
1996 Kim 18 0.0 5.6 0.0 27.8 5.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0    38.9 
1995 Monk 53  1.9  50.9 5.7                60.0 
                        
Pooled prevalence  197 5.8 5.2 0.0 52.3 5.2 1.7 7.5 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 65.3 
95% CI, lower    2.8 0.0 45.3 2.8 0.5 4.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0  
95% CI, upper    9.6 3.1 59.1 9.6 5.9 13.6 2.6 3.1 3.1 3.1 4.6 3.1 3.1 3.1 3.1 3.1 3.6 3.6 4.3  
                        
Multitype adjusted  120  3.6 0.0 49.5 4.2 1.7 6.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0  
95% CI, lower    1.4 0.0 40.7 1.8 0.5 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0  
95% CI, upper    8.6 3.1 58.3 9.5 5.9 11.8 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.1 3.6 3.6 4.3  
*

As determined by consensus PCR primers sensitive to positivity for at least 15 HPV types.

Data for additional cases and HPV typing provided by the authors. In the study, HPV testing methods changed over time. Early testing of specimens (n = 24) was conducted for individual HPV types 16 and 35 (HPV testing for types 6/11, 18/45, and 31/33 were combined in single cocktails). Later testing was conducted for a much broader spectrum of individual HPV types (n = 86). In the table, prevalence data are reported across all specimens for HPV types 16 and 35, whereas only specimens tested during the latter period are included in results for the remaining HPV types as earlier testing for these types individually was not conducted. Only specimens tested during the latter period are included in the multitype adjusted HPV data, as the earlier testing covered <8 individually evaluable HPV types.

n refers to total number of lesions with any HPV typing data. By individual HPV type, number of observations varies depending on the number of types for which data were available within each study.

Close Modal

or Create an Account

Close Modal
Close Modal